Gene Editing, Genetic Engineering and In-Vivo

Poseida Joins Roche in $1.5B Deal to Deliver Next-Gen CAR-T Therapies

XTalks

NOVEMBER 29, 2024

129 Through this acquisition, Roche secures proprietary technologies such as Poseida’s Cas-CLOVER gene editing platform and in-house good manufacturing practice (GMP) manufacturing capabilities. Poseida’s genetic engineering platforms stand out for their precision, safety and potential to open new therapeutic avenues.

Gene Therapy

Gene Therapy Gene Gene Editing In-Vivo

Zebrafish Model Uncovers Promising Therapies for Ultra-Rare Genetic Disorder

Scienmag

JUNE 5, 2025

In a remarkable convergence of genetic research and innovative animal modeling, scientists have unveiled a groundbreaking approach to understanding and potentially treating an exceptionally rare inherited muscle disorder known as X-linked myopathy with excessive autophagy (XMEA).

Genetics

Genetics Gene Genome Genomics

Clinical Research Informer

Poseida Joins Roche in $1.5B Deal to Deliver Next-Gen CAR-T Therapies

Zebrafish Model Uncovers Promising Therapies for Ultra-Rare Genetic Disorder

Webinars

Stay Connected